Understanding how alpha-1 antitrypsin deficiency damages the liver
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study follows adults with a genetic condition called alpha-1 antitrypsin deficiency (a rare protein deficiency) who have liver disease. Researchers will examine stored blood and tissue samples to understand why some people's livers are damaged more than others, which may help develop better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been genetically confirmed to have alpha-1 antitrypsin deficiency (specific Pi*ZZ type)
- You have at least 5 years of medical records and follow-up visits in the alpha-1 antitrypsin disease registry
- You had at least one liver assessment that included a stiffness measurement and blood tests for liver damage markers
- You have stored blood samples available for research analysis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study screens for a rare genetic condition called Alpha-1 Antitrypsin Deficiency in people with lung blockage. It aims to find out if this deficiency is a hidden cause of your breathing problems, which could lead to better treatment options.
This trial tests a new medicine called TSRA-196 for people with Alpha-1 Antitrypsin Deficiency who have the PiZZ genetic type. The study looks at whether TSRA-196 can help with lung or liver problems related to this condition.
This study looks at how alpha-1 antitrypsin deficiency affects the liver in adults. It aims to learn more about the liver problems caused by this condition and may help find better ways to manage them.
This study looks for a rare cause of liver cancer called alpha-1 antitrypsin deficiency in people whose liver cancer is not due to common causes like alcohol, hepatitis, or fatty liver. If you fit, it could help find an underlying reason for your cancer.
This study checks whether doing alpha-1 screening (genetic test and a blood level test) can help identify alpha-1 antitrypsin deficiency in people at risk. It may be useful if you have symptoms or a family history, but you haven’t had qualifying testing yet.
This study tests whether a protein called alpha-1 antitrypsin can help people with severe alcoholic hepatitis, a serious liver condition caused by heavy drinking. If it works, it may reduce liver damage and improve recovery.
Hear when a new Alpha 1-antitrypsin Deficiency (AATD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.